Antisense therapeutics
- 31 December 1998
- journal article
- review article
- Published by Elsevier in Current Opinion in Chemical Biology
- Vol. 2 (4) , 519-528
- https://doi.org/10.1016/s1367-5931(98)80129-4
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Mixed Backbone Oligonucleotides: Improvement in Oligonucleotide-induced Toxicity In VivoAntisense and Nucleic Acid Drug Development, 1998
- High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremitiesOncogene, 1998
- Toxicologic Effects of an Oligodeoxynucleotide Phosphorothioate and Its Analogs Following Intravenous Administration in RatsAntisense and Nucleic Acid Drug Development, 1997
- Pattern and Kinetics of Cytokine Production Following Administration of Phosphorothioate Oligonucleotides in MiceAntisense and Nucleic Acid Drug Development, 1997
- In VivoPharmacokinetics of Phosphorothioate Oligonucleotides Containing Contiguous GuanosinesAntisense and Nucleic Acid Drug Development, 1997
- In VivoMetabolic Profile of a Phosphorothioate OligodeoxyribonucleotideAntisense and Nucleic Acid Drug Development, 1997
- PHOSPHOROTHIOATE OLIGONUCLEOTIDE METABOLISM: CHARACTERIZATION OF THE “N+”-MER BY CE AND HPLC-ES/MSBioorganic & Medicinal Chemistry Letters, 1997
- Distribution of the Cellular Uptake of Phosphorothioate Oligodeoxynucleotides in the Rat Kidney in vivoNephron, 1997
- Immune Activation by Bacterial DNA: A New Genetic CodeImmunity, 1996
- Recent status of the antisense oligonucleotide approaches in oncologyFundamental & Clinical Pharmacology, 1996